Results 121 to 130 of about 3,089,193 (316)
WHO special project for pharmaceuticals in Newly Independent States (NIS) : strategic approaches [PDF]
, 2003 The Special Project on Pharmaceuticals in the Newly Independent States (NIS), which includes all former USSR countries except the Baltic countries, was established within the WHO European Office (Copenhagen, Denmark) in 1993 to meet the specific needs of
Saoutenkova, Nina
core
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
Molecular Oncology, EarlyView.Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon +13 more
wiley +1 more source
Welcoming Workplace: Rapid Design Intervention to Determine the Office Environment Needs of Older Knowledge Workers [PDF]
, 2010 This book chapter details the context, methods, findings and implications of the Welcoming Workplace project (RCA, 2006–8), which was part of Phase 2 of the Designing for the 21stCentury Research Programme (AHRC-EPSRC), directed by Professor Tom Inns ...
Bichard, Jo-Anne, Myerson, Jeremy
core
Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin
Molecular Oncology, EarlyView.The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla +10 more
wiley +1 more source
Molecular Oncology, EarlyView.We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Behaviour change at work: Empowering energy efficiency in the workplace through user-centred design [PDF]
, 2011 Copyright @ 2011 University of California eScholarship RepositoryCO2 emissions from non-domestic buildings - primarily workplaces - make up 18 percent of the UK's carbon footprint.
Cain, R +5 more
core +1 more source
Molecular Oncology, EarlyView.Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
Student Education During The REXUS/BEXUS Projects [PDF]
, 2009 The new DLR Institute of Space Systems in Bremen has established a project office to support and manage German student activities related to the preparation of the BEXUS and REXUS (Balloon/Rocket Experiments for University Students) flights.
Hellmann, Harald +3 more
core